Pipeline

  PRODUCT/INDICATION PRE CLINICAL PHASE 1 PHASE 2 PHASE 3 NDA Submitted FDA Approved
Baxdela™ (delafloxacin)
Serious Skin Infections (ABSSSI)
IV-ORAL FORMULATIONS (QIDP)
IV (QIDP)
Oral (QIDP)
Serious Community-Acquired Bacterial Pneumonia (CABP)
IV-ORAL (QIDP)
(QIDP)
Complicated Urinary Tract Infections (cUTI)
IV-ORAL
(QIDP ELIGIBLE)
Solithromycin
Community acquired bacterial pneumonia (CABP)
Oral (QIDP)
IV-to-oral (QIDP)
Pediatric (QIDP)
Urethritis / gonorrhea
Oral
Conjunctivitis / blepharitis /dry eye
Ophthalmic
Fusidic Acid
Skin infections (ABSSSI)
Oral (QIDP)
Chronic bone and joint infections
Oral
Proprietary Discovery Platform
Radezolid: 2nd generation oxazolidinone for acne vulgaris
Topical
ESKAPE* Program: novel pyrrolocytosine
“SUPER-BUGS”
Macrolide Program
NEXT-GEN
PRODUCT/INDICATION DELIVERY/PHASE
Baxdela™ (delafloxacin)
Serious Skin Infections (ABSSSI)
IV-ORAL FORMULATIONS (QIDP)
IV (QIDP) / FDA Approved
Oral (QIDP) / FDA Approved
Serious Community-Acquired Bacterial Pneumonia (CABP)
IV-ORAL (QIDP)
(QIDP) / Phase 3
Complicated Urinary Tract Infections (cUTI)
IV-ORAL
(QIDP ELIGIBLE) / Phase 1
Solithromycin
Community acquired bacterial pneumonia (CABP)
Oral (QIDP) / NDA Submitted
IV-to-oral (QIDP) / NDA Submitted
Pediatric (QIDP) / Phase 3
Urethritis / gonorrhea
Oral / Phase 3
Conjunctivitis / blepharitis /dry eye
Ophthalmic / Preclinical
Fusidic Acid
Skin infections (ABSSSI)
Oral (QIDP) / Phase 3
Chronic bone and joint infections
Oral / Phase 2
Proprietary Discovery Platform
Radezolid: 2nd generation oxazolidinone for acne vulgaris
TOPICAL / Phase 2
ESKAPE* Program: novel pyrrolocytosine
“SUPER-BUGS” / Preclinical
Macrolide Program
NEXT-GEN / Preclinical
  • ABSSSI: Acute bacterial skin and skin structure infections || CABP: Community-acquired bacterial pneumonia || cUTI: Complicated urinary tract infections || ESKAPE: The ESKAPE pathogen program includes a focus on multidrug- and extremely-drug-resistant versions of the following pathogens: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species and Escherichia coli || QIDP: Qualified Infectious Disease Product || SPA: Special Protocol Assessment

Melinta Therapeutics’ lead therapy, Baxdela (delafloxacin), is FDA approved in the US for the treatment of serious skin infections known as acute bacterial skin and skin structure infections (ABSSSI). For more information about Baxdela for treatment of ABSSSI, please visit www.Baxdela.com.